Sanofi and Regeneron Pharmaceuticals Inc. look set to exploit a third indication for their monoclonal antibody product, Dupixent (dupilumab), after the product hit its co-primary and all secondary endpoints in two Phase III trials in patients with adults with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
The data come as the companies await an US FDA decision on the approval of Dupixent in its second indication, moderate-to-severe asthma, later this week (19 Oct.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?